Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 10/20 | 0.52 |
| ▸ | RARA | P10276 | 2/20 | 0.52 |
| ▸ | RARG | P13631 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MTOR | P42345 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.38 |
| ▸ | PLK1 | P53350 | 1/20 | 0.37 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1816914 | 0.95 | RARB (0.57) | RARBRARARARGTSHRHSD17B10 | |
| SCHEMBL10030230 | 0.93 | RARB (0.56) | RARBRARARARGTSHRHSD17B10 | |
| SCHEMBL16258064 | 0.91 | RARB (0.53) | RARBRARARARGTSHRHSD17B10 | |
| SCHEMBL16258027 | 0.88 | RARB (0.53) | RARBRARARARGTSHRHSD17B10 | |
| SCHEMBL12198992 | 0.88 | RARB (0.43) | RARBRARARARGMAPT | |
| SCHEMBL16258059 | 0.86 | RARB (0.48) | RARBRARARARGGPR84 | |
| SCHEMBL14175167 | 0.86 | RARB (0.66) | RARBRARARARGTSHRHSD17B10 | |
| SCHEMBL12622913 | 0.85 | RARB (0.48) | RARBRARARARGTSHRHSD17B10 | |
| SCHEMBL15461666 | 0.85 | RARB (0.58) | RARBRARARARGTSHRHSD17B10 | |
| SCHEMBL13239276 | 0.85 | RARB (0.58) | RARBRARARARGTSHRHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7951433-B2 | Five-ring liquid crystal compound having CF2O bonding group, liquid crystal composition, and liquid crystal display device | CHISSO CORPORATION (JP) | 2011-05-31 | — | — | US | disclosed |
| US-20100127211-A1 | FIVE-RING LIQUID CRYSTAL COMPOUND HAVING CF20 BONDING GROUP, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | CHISSO CORPORATION (JP) | 2010-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100127211-A1 | FIVE-RING LIQUID CRYSTAL COMPOUND HAVING CF20 BONDING GROUP, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | CFAP20, KIF20A, KIF20B | RARB 2364/4885RARA 1623/4885RARG 2760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.